These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 23650874)

  • 1. Role of immunotherapy in castration-resistant prostate cancer (CRPC).
    Suárez C; Morales-Barrera R; Ramos V; Núñez I; Valverde C; Planas J; Morote J; Maldonado X; Carles J
    BJU Int; 2014 Mar; 113(3):367-75. PubMed ID: 23650874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.
    Gomella LG; Gelpi-Hammerschmidt F; Kundavram C
    Can J Urol; 2014 Apr; 21(2 Supp 1):48-56. PubMed ID: 24775724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evolving role of immunotherapy in prostate cancer.
    Gerritsen WR
    Ann Oncol; 2012 Sep; 23 Suppl 8():viii22-7. PubMed ID: 22918924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.
    Di Lorenzo G; Ferro M; Buonerba C
    BJU Int; 2012 Jul; 110(2 Pt 2):E99-104. PubMed ID: 22177289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutic vaccines is a novel approach in castration-resistant prostate cancer treatment].
    Djurhuus SS; Brasso K; Berg KD; Iversen P; Røder MA
    Ugeskr Laeger; 2015 May; 177(20):. PubMed ID: 25967247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequencing of agents for castration-resistant prostate cancer.
    Hurwitz M; Petrylak DP
    Oncology (Williston Park); 2013 Nov; 27(11):1144-9, 1154-8. PubMed ID: 24575543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current role of immunotherapy for the treatment of prostate cancer.
    Porfyris O; Kalomoiris P
    J BUON; 2013; 18(4):809-17. PubMed ID: 24344002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integration of immunotherapy into the management of advanced prostate cancer.
    Kantoff P; Higano CS
    Urol Oncol; 2012; 30(5 Suppl):S41-7. PubMed ID: 23040162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The treatment of castration-resistant prostate cancer].
    Petrányi Á
    Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions.
    Wei XX; Fong L; Small EJ
    Expert Rev Vaccines; 2015; 14(12):1529-41. PubMed ID: 26488270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel therapeutics for the management of castration-resistant prostate cancer (CRPC).
    Lee DJ; Cha EK; Dubin JM; Beltran H; Chromecki TF; Fajkovic H; Scherr DS; Tagawa ST; Shariat SF
    BJU Int; 2012 Apr; 109(7):968-85. PubMed ID: 22035221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to approach sequencing therapy in patients with metastatic castration resistant prostate cancer.
    Dreicer R
    Can J Urol; 2014 Apr; 21(2 Supp 1):93-7. PubMed ID: 24775730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Castration-resistant prostate cancer: from new pathophysiology to new treatment.
    Sridhar SS; Freedland SJ; Gleave ME; Higano C; Mulders P; Parker C; Sartor O; Saad F
    Eur Urol; 2014 Feb; 65(2):289-99. PubMed ID: 23957948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond sipuleucel-T: immune approaches to treating prostate cancer.
    Cheng ML; Fong L
    Curr Treat Options Oncol; 2014 Mar; 15(1):115-26. PubMed ID: 24402184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New treatment options for patients with metastatic castration-resistant prostate cancer.
    Higano CS
    Cancer Treat Rev; 2012 Aug; 38(5):340-5. PubMed ID: 21944872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T.
    Quinn DI; Vaishampayan U; Higano CS; Lin DW; Shore ND; Beer TM
    Expert Rev Anticancer Ther; 2014 Jan; 14(1):51-61. PubMed ID: 24224900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy.
    Mulders PF; De Santis M; Powles T; Fizazi K
    Cancer Immunol Immunother; 2015 Jun; 64(6):655-63. PubMed ID: 26025563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer: current progress and clinical applications.
    Gulley JL; Madan RA; Heery CR
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastatic castration-resistant prostate cancer. Part 1: the challenges of the disease and its treatment.
    Bahl A
    Eur J Oncol Nurs; 2013 Sep; 17 Suppl 1():S1-6. PubMed ID: 24461207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy.
    Wei XX; Perry J; Chang E; Zhang L; Hiatt RA; Ryan CJ; Small EJ; Fong L
    Clin Genitourin Cancer; 2018 Jun; 16(3):184-190.e2. PubMed ID: 29352713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.